论文部分内容阅读
目的探讨开创恶性肿瘤早期诊断方法,提高早期诊断技术。方法对3031例恶性肿瘤、白血病、MDS、良性肿瘤及其它各种不同疾病病人,及正常对照组540例进行检测,综合分析,找出相关性,揭示p值变化。结果微核细胞率,恶性肿瘤异常增高,并出现在癌变细胞及白前变细胞之前,其诊断准确率较高93.6%,假阳性假阴性6.4%,DNA异倍体虽然是诊断恶性肿瘤重要方法,但诊断准确率仅占65.2%,假阳性假阴性占34.8%。但通过微核及DNA异倍体联合测定,提高了对恶性肿瘤早期诊断水平。结论两法联合测定不仅弥补一种方法的不足,排除了干扰,提高了对恶性肿瘤及白血病早期诊断的符合率,并对药物选择、疗效观察、预后评估更具有前瞻性早期诊断价值。
Objective To explore the method of early diagnosis of malignant tumor and improve the early diagnosis technique. Methods A total of 5401 patients with malignant tumor, leukemia, MDS, benign tumor and other various diseases and normal control group were enrolled in this study. A total of 540 cases were detected and analyzed to find out the correlation and reveal the p value. Results The rates of micronucleated cells and malignant tumors were significantly higher than those before carcinogenic cells and precancerous cells. The diagnostic accuracy rate was 93.6% and the false positive false negative rate was 6.4%. DNA aneuploidy was an important method for the diagnosis of malignant tumors , But the diagnostic accuracy rate accounted for only 65.2%, false positive false negatives accounted for 34.8%. However, the combination of micronuclei and DNA aneuploidy increased the early diagnosis of malignant tumors. Conclusion The combination of the two methods not only make up for the lack of one method, but also eliminate the interference and improve the coincidence rate of early diagnosis of malignant tumor and leukemia. And it has more prospective and early diagnostic value for drug selection, curative effect observation and prognosis evaluation.